多元参与视域下突发事件网络舆情治理的警示与策略——基于“洁洁良”事件的分析

突发网络舆论事件日益增多,厘清突发事件网络舆情治理的应对危机对提高其治理效能具有重要意义。经由"洁洁良"事件的典型案例分析,基于多元参与的视角归纳出媒体、网民和舆论对象三元主体在突发事件网络舆情治理中的行为风险。为有效化解突发事件网络舆情治理的风险、困境与危机,当前提升突发事件网络舆情治理的效能需完善事前预警与回应相结合的前置性治理策略,加强事中引导与化解相结合的综合性治理策略以及巩固事后归纳与教育相结合的隐藏性治理策略。

“洁洁良”事件的本质映射与思想政治教育反思

"洁洁良"事件的产生,在一定程度上反映出高校大学生政治意识"淡化",政治行为"粗鲁"和政治参与"冷漠",究其背后的原因,是高校思想政治教育方面出现了缺位现象,具体表现为教育理念层面的堆积捆绑挟持本位主体、内容上的因循守旧绑架实质创新、方式手段上的迎合媚俗弱化主流渠道,教育主体鱼龙混杂制约教育效果。应坚定不移坚持政治核心地位,坚定不移推动高校思想政治教育的改革创新等,进一步推动高校思想政治教育工作适应时代发展的需要。

Hepatoxicity associated with weight-loss supplements: A case for better post-marketing surveillance

There is a growing number of case reports of hepatoxicity from the widely marketed weight-loss supplement Hydroxycut, which contains the botanical ingredient Garcinia cambogia . These case reports may substantially undercount the true magnitude of harm. Based on the past experience with harmful dietary supplements, US regulators should assume the more precautionary approach favored by Canada and Europe. Lacking effective adverse event surveillance for supplements, or the requirements to prove safety prior to coming to the market, case reports such as those summarized here assume added importance.

Effects of adjuvant Chinese patent medicine therapy on major adverse cardiovascular events in patients with coronary heart disease angina pectoris:a population-based retrospective cohort study

Objective: This study aimed to explore the effects of Chinese patent medicine(CPM) in reducing the incidence of major adverse cardiovascular events(MACE) in patients with coronary heart disease(CHD) angina pectoris and improving clinical effectiveness and provide evidence for its use as clinical adjuvant therapy.Methods: Twenty-eight thousand five hundred and seventeen patients hospitalized with CHD angina pectoris from 6 hospitals were divided into CPM group(n = 11,374) and non-CPM group(n = 17,143) to evaluate the incidence of MACE, including myocardial infarction, percutaneous coronary intervention, and coronary artery bypass grafting.Results: The incidence of MACE in the CPM group was lower than that in the non-CPM group. CPM therapy was an independent protective factor that reduced the overall risk of MACE [adjusted hazard ratio = 0.40, 95% confidence interval(0.33;0.49)]. Patients in the CPM group who received one, two, or three types of CPM could benefit from adjuvant treatment with CPM, and taking more types of CPM was associated with a lower risk of MACE. In addition, the male population was better than the female population at taking CPM, and middle-aged people aged 55 to 64 were more suited to take CPM based on Western medicine.Conclusions: The use of CPM as adjuvant therapy can decrease the occurrence of MACE in patients with CHD angina pectoris,especially in men and middle-aged people, and the drug treatment plan should be optimized accordingly. However, this conclusion needs further verification by prospective cohort studies in the future.

强化健康宣教对维持性血透患者护理质量的影响研究

分析强化健康宣教在维持性血透患者护理中的效果和作用。方法 研究时间段选择为2022年9月到2023年4月,在收治的血透患者中抽选65例,并且将其划分为研究组与参照组。给予研究组强化健康宣教的宣教方式,给予参照组常规宣教方式,最后比较研究组和参照组患者护理后的生活质量、不良事件发生、体重变化情况以及疾病知识知晓情况。结果 搜集患者的各项数据并进行统计和分析,研究组患者的生活质量得分比参照组更高,数据差异显着(P<0.05);研究组患者发生不良事件的情况更少,治疗安全性和效果得到保证(P<0.05;研究组患者的体重维持得更好,体重达标率比参照组更高,差异显着(P<0.05);根据问卷可知,研究组患者对疾病相关知识的得分更高,掌握情况比参照组好,差异显着(P<0.05)。结论 将强化健康宣教用于维持性血透患者的护理中,可有效增加患者降低患者不良事件发生率,提高患者的生活质量,让患者的自我管理意识得到加强,健康知识掌握较好,对疾病治疗具有积极意义。

既往胃镜检查对评估经皮冠脉介入术后非急性冠脉综合症患者是否联用质子泵抑制剂的作用

目的探讨经皮冠脉介入术（PCI）前非急性冠脉综合症（非ACS）患者既往胃镜检查对PCI术后综合评估联用质子泵抑制剂（PPIs）的风险和获益的重要意义。方法回顾性分析673例行PCI术放置冠脉支架的非ACS患者，先将其分为PPIs联用组和未联用组，然后根据与上消化道不良事件密切相关的危险因素再分高、中、低危亚组，分别比较各组心血管和上消化道不良事件发生率的差别以及既往胃镜检查情况。结果PCI术前5年内仅12．2％（82／673）的患者曾行胃镜检查，消化性溃疡的总体检出率为32．9％（27／82），PPIs联用组占55．6％（15／27）。PPIs联用组患者的心血管不良事件发生率显著高于未联用组（22．6％比8．9％，P〈0．01），其中以消化道高危患者（16．4％，24／146）的心血管不良事件发生率最高（41．7％，10／24），但其上消化道不良事件发生率最低（4．2％，1／24）。90．5％（344／380）的中危患者是年龄I〉65岁且联用NSAIDs等药物者，其在PCI术前5年内行胃镜检查的比例显著低于既往有上消化道病史且联用NSAIDs等药物者（PPIs联用组：14．1％比54．5％，P〈0．01；未联用组：7．5％比28．0％，P〈0．01），在PPIs联用组前者心血管不良事件发生率显著高于后者（20．5％比9．1％，P〈0．01），但两者在PCI术后1年内上消化道不良事件的发生率相近（9．0％比9．1％，P〉0．05）。结论PCI术前既往胃镜检查可提供上消化道基础疾病信息，有助于PCI术后合理应用PPIs，减少心血管不良事件的发生。年龄I〉65岁且联用NSAIDs等药物的中危患者是需重点关注的人群。

Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes:a randomized,double-blind,phase 3 trial(CMAS)

Chiglitazar(Carfloglitazar)is a novel peroxisome proliferator-activated receptor(PPAR)pan-agonist that has shown promising effects on glycemic control and lipid regulation in patients with type 2 diabetes.In this randomized phase 3 trial,we compared the efficacy and safety of chiglitazar with sitagliptin in patients with type 2 diabetes who had insufficient glycemic control despite a strict diet and exercise regimen.Eligible patients were randomized(1:1:1)to receive chiglitazar 32 mg(n=245),chiglitazar 48 mg(n=246),or sitagliptin 100 mg(n=248)once daily for 24 weeks.The primary endpoint was the change in glycosylated hemoglobin A_(1C)(HbA_(1c))from baseline at week 24 with the non-inferiority of chiglitazar over sitagliptin.Both chiglitazar and sitagliptin significantly reduced HbA1c at week 24 with values of-1.40%,-1.47%,and-1.39%for chiglitazar 32 mg,chiglitazar 48 mg,and sitagliptin 100 mg,respectively.Chiglitazar 32 and 48 mg were both non-inferior to sitagliptin 100 mg,with mean differences of-0.04%(95%confidential interval(Cl)-0.22 to 0.15)and-0.08%(95%Cl-0.27 to 0.10),respectively.Compared with sitagliptin,greater reduction in fasting and 2-h postprandial plasma glucose and fasting insulin was observed with chiglitazar.Overall adverse event rates were similar between the groups.A small increase in mild edema in the chiglitazar 48 mg group and slight weight gain in both chiglitazar groups were reported.The overall results demonstrated that chiglitazar possesses good efficacy and safety profile in patients with type 2 diabetes inadequately controlled with lifestyle interventions,thereby providing adequate supporting evidence for using this PPAR pan-agonist as a treatment option for type 2 diabetes.

Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes:a prospective,randomized,double-blind,phase 3 trial

Ultra rapid lispro(URLi)is a novel formulation of insulin lispro designed to more closely match the physiological insulin response to a meal,with the aim of improving postprandial glucose(PPG)control.We conducted a multinational,multicenter,randomized,double-blind,treat-to-target,26-week,phase 3 trial to evaluate the efficacy and safety of URLi in adults with type 2 diabetes(T2D).After an 8-week lead-in period during which basal insulin glargine or degludec was optimized,adults with T2D were randomized(2:1)to prandial URLi(n=395)or lispro(n=200).The primary endpoint was non-inferiority of URLi versus lispro in glycated hemoglobin A1c(HbA_(1c))change from baseline to week 26.Multiplicity-adjusted analyses were performed to assess the superiority of URLi in 1-and 2-h PPG excursions during a mixed-meal tolerance test(MMTT)and HbA_(1c) change at week 26.URLi showed non-inferiority for Hb Achange at week 26 versus lispro(least-squares mean[LSM]difference,0.07%;95%confidence interval:-0.07,0.21).HbA_(1c) was reduced by 0.56%and 0.63%with URLi and lispro,respectively,with no significant treatment difference(P=0.321).URLi provided superior PPG excursion control versus lispro at1 h(LSM difference:-14.6 mg/d L,P<0.001)and 2 h(LSM difference:-21.8 mg/d L,P<0.001)as well as other time points(30–240 min)during the MMTT.Incremental area under the glucose curve during the MMTT was also significantly lower with URLi versus lispro.The safety profiles were generally similar between treatment groups.In conclusion,URLi was superior to lispro for PPG control,with noninferiority in HbA_(1c) improvement,in adults with T2D.